Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings. Near-term, if one ...

The Dogs for the Disabled charity has secured a brand new premises in Cork - which will slash waiting times for people in ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

Neurotech says Dr Anthony Filippis will leverage partnering success and capital markets expertise to progress its NTI164 ...

including myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). In DM1, Avidity Biosciences continues to progress with their Phase 3 ...

A Pennsylvania woman, 38, tells PEOPLE that she credits Dateability, a dating app focused on the disabled and chronically ill ...

WHAT IT'S ABOUT The documentary "The Remarkable Life of Ibelin" tells the story of Mats Steen, a Norwegian man with Duchenne ...

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

Zolgensma gene therapy is the most effective in infants with SMA who are presymptomatic and 6 weeks old or younger, according ...